Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
And it is interesting that a missense mutation in SPRED1 and a splice region mutation in C3 are found in the psoriasis individuals in the other two MZ twin pairs without carrying HLA-C*0602 allele.
|
31629629 |
2020 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of HLA-C*0602 allele (4.1%) was lower than in patients with plaque-type psoriasis (4.1 vs. 16.3%, corrected p value [P<sub>c</sub>] = 0.02) and similar to that in the healthy population in Taiwan.
|
31820331 |
2020 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We sought to test whether HLA-C*06:02, the primary genetic susceptibility allele for psoriasis, predisposes patients to respond differently to the 2 most commonly prescribed biologics for psoriasis: adalimumab (anti-TNF-α) and ustekinumab (anti-IL-12/23).
|
30578879 |
2019 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies were included if they reported the association between HLA-C*06:02 status and 75% improvement in Psoriasis Area and Severity Index (PASI75) response to ustekinumab therapy in patients with plaque psoriasis after 6 and/or 3 months of treatment.
|
30994858 |
2019 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This includes the association of psoriasis with certain MHC (HLA) alleles, oligoclonal expansion of T cells in some cases, therapeutic response to T cell-directed immunomodulation, the onset of psoriasis following bone marrow transplantation, or induction of psoriasis-like inflammation by T cells in experimental animals.
|
31402919 |
2019 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Author Correction: Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis.
|
31123311 |
2019 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regression analysis showed that the LoPsA group at presentation was characterized by: less males (OR 0.4, p = 0.001), less HLA-C*06 (OR 0.3, p = 0.005), longer psoriasis duration (OR 1.04, p = 0.0005), higher BMI (OR 1.1, p = 0.005) and higher modified Steinbrocker score (mSS) (OR 1.1, p = 0.005).
|
30243758 |
2019 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of <i>HLA-C*06</i> or rs26653 G allele significantly increased the risk of psoriasis by 2.4 times or twice, respectively.
|
30008647 |
2018 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis.
|
29259305 |
2018 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other MHC-I-opathies include ankylosing spondylitis and HLA-B*27-associated spondyloarthropathies and HLA-C*0602-associated skin psoriasis.
|
28898393 |
2018 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An ERAP1 haplotype known to possess high enzymatic activity was associated with psoriasis if HLA-C*06:02 was present and a functional ERAP2 allele was absent.
|
29183862 |
2018 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The unbiased analysis of a paradigmatic Vα3S1/Vβ13S1-T-cell receptor from a pathogenic epidermal CD8<sup>+</sup> T-cell clone of an <i>HLA-C*06:02</i><sup>+</sup> psoriasis patient had revealed that HLA-C*06:02 directs an autoimmune response against melanocytes through autoantigen presentation, and it identified a peptide form ADAMTS-like protein 5 as an HLA-C*06:02-presented melanocyte autoantigen.
|
29760713 |
2018 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we showed a HLA-C*06:02-independent gender-related effect of the rs887466A allele which was protective against psoriasis in males (OR = 0.61, p = 9.2e-005), but not in females (p = 0.66).
|
29589160 |
2018 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Further analysis with imputed classical HLA alleles suggested the known psoriasis risk allele <i>HLA-C*06:02</i> as a risk factor for tonsillitis (<i>P</i> = 4.8 × 10<sup>-4</sup>; OR, 2.3).
|
30037793 |
2018 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four inflammatory diseases are strongly associated with Major Histocompatibility Complex class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A<sup>*</sup>29:02), ankylosing spondylitis (HLA-B<sup>*</sup>27), Behçet's disease (HLA-B<sup>*</sup>51), and psoriasis (HLA-C<sup>*</sup>06:02).
|
30425713 |
2018 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expanding on the previously reported experience with this patient, we conclude that HLA-C*18:01 probably indicates a severe, recalcitrant, multidrug-resistant psoriasis phenotype for which proper therapy remains to be identified.
|
30076588 |
2018 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Case-control analysis revealed an association of IL12B rs3212227 and IL23R rs11209026 minor allele carrier status with reduced odds for psoriasis (OR = 0.66, 95%CI: 0.50-0.87, and OR = 0.41, 95%CI: 0.26-0.67, respectively), while HLA-C*06 allele carriers were more frequent in patients group (OR = 4.56, 95%CI: 3.41-6.10).
|
29454820 |
2018 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, when combining the results of both the stepwise regression analysis and the HLA-C*06:02 conditioning analysis, different variants were found to be independently associated with each psoriasis subgroup.
|
29076194 |
2017 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PSORS1C2 is a gene located between coiled-coil alpha-helical rod protein 1 (CCHCR1) and corneodesmosin (CDSN) within the psoriasis susceptibility locus 1 (PSORS1).
|
27943452 |
2017 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Deletion of two members, LCE3B and LCE3C (LCE3B/C-del), is a widely-replicated psoriasis risk factor that interacts with the major psoriasis-psoriasis risk gene HLA-C*06.
|
28634035 |
2017 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Deletion of late cornified envelope (LCE) genes LCE3B and LCE3C (LCE3B/C-del) is a psoriasis risk factor linked to the major psoriasis risk gene HLA-C*06.Niehues et al. demonstrate that LCE3B/C-del leads to increased keratinocyte LCE3A expression.
|
29055413 |
2017 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association between geographic tongue and psoriasis has been demonstrated in various studies, based on observation of its fundamental lesions, microscopic similarity between the two conditions and the presence of a common genetic marker, human leukocyte antigen (HLA) HLA-C*06.
|
27579734 |
2017 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
After controlling for the age of psoriasis onset no association of PsA to HLA-C*06:02 (p=0.07) was observed; instead, the most significant association was to amino acid at position 97 of HLA-B (p=1.54×10<sup>-9</sup>) where the presence of asparagine or serine residue increased PsA risk.
|
28821532 |
2017 |
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have investigated the association and possible functional role of non-synonymous SNPs at different exons of ERAP1 (rs26653: Arg127Pro, rs30187: rs30187" genes_norm="51752">Lys528Arg and rs27044: rs27044" genes_norm="51752">Gln730Glu) and their interactions with HLA-C∗06 in psoriasis.
|
28867178 |
2017 |
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the structural basis of this selectivity, we determined crystal structures of HLA-C*06:02 in complex with two self-peptides (ARTELYRSL and ARFNDLRFV) and an analogue of a melanocyte autoantigen (ADAMTSL5, VRSRR-abu-LRL) implicated in psoriasis.
|
28855257 |
2017 |